«上一篇/Previous Article|本期目录/Table of Contents|下一篇/Next Article»

《慢性病学杂志》[ISSN:1674-8166/CN:11-5900/R]

卷:

21

期数:

2020年02期

页码:

205-208

栏目:

论　著

出版日期:

2020-02-28

文章信息/Info

Title:

Influence of liraglutide injection on clinical efficacy and satisfaction of obese patients with type2diabetes mellitus

作者:

顾晔

苏州太平糖尿病内分泌医院，江苏 苏州 215137

Author(s):

GUYe

TaipingDiatebes Endocrinology Hospitalof Suzhou,Suzhou215137,Jiangsu,China Correspondingauthor：GUYe,E-mail:ct6zz8@163.com

关键词:

2型糖尿病; 肥胖; 利拉鲁肽; 满意度

Keywords:

Type2 diabetes;  Obesity;  Liraglutide;  Satisfaction

分类号:

R587.1

DOI:

-

摘要:

目的 探讨利拉鲁肽注射液对肥胖2型糖尿病（T2DM）患者的临床疗效及满意度的影响。方法 选取 苏州太平糖尿病内分泌医院收治的68例T2DM患者，均在原胰岛素治疗基础上加用利拉鲁肽注射液治疗12周； 第1周利拉鲁肽注射剂量为0.6 mg/d，第2周注射剂量为1.2 mg/d，第3周开始注射剂量为1.8 mg/d。受试者在 治疗前后接受糖尿病治疗满意度调查问卷；同时记录糖化血红蛋白（HbA1c）、空腹血糖（FBG）、每日胰岛素总 剂量（TDD）、每日胰岛素注射次数及每周低血糖发生频率等。结果 与治疗前相比，治疗后患者在降糖方案 满意度、疗效满意度、糖尿病相关知识的了解程度等方面均有明显提高（均P<0.05）。经过12周治疗，患者的 FBG、HbA1c、TDD、体质量水平较治疗前均明显下降（P<0.05），每日胰岛素注射次数及每周低血糖发生频率 比治疗前减少（P<0.05）。结论 在原胰岛素治疗方案上增加利拉鲁肽注射液，除了可以有效改善肥胖T2DM 患者的血糖、HbA1c水平，还提高了糖尿病治疗满意度，降低了低血糖/高血糖事件的发生频率。

Abstract:

Objective To investigate the effect of liraglutide injection on clinical efficacy and satisfaction of obese patients with type 2 diabetes mellitus. Methods A total of68 obese patients with type 2 diabetes were enrolled from Taiping Diatebes Endocrinology Hospital of Suzhou. All patients were treat-ed with liraglutide for 12 weeks on the basis of pro-insulin therapy. The liraglutide was administered at a dose of 0.6 mg/d,1.2 mg/d,1.8 mg/d, respecively, at the first, second, third week. Subjects received a questionnaire on satisfaction about diabetes treatment before and after treatment, at the same time, recording glycosylated hemoglobin （HbA1c）, fasting blood glucose（FBG）, total daily insulin dose（TDD）, daily insulin injections times, and frequency of weekly hypoglycemia. Results Com-pared with before treatment, these indexes such as satisfaction of hypoglycemic regimen, efficacy, the understanding degree about knowledge of diabetes mellitus, etc, were all significantly improved after treatment（all P<0.05）. After the treatment for twelve weeks, the FBG, HbA1c, TDD, body mass levels of patients were all decreased, and the times of insulin injections and the hypoglycemia frequen-cy were all resuced than those before treatment, and there were all significantly different （all P< 0.05）. Conclusions On the basis of pro-insulintreatment, liraglutide injection can effectively improve the blood glucose and glycosylated hemoglobin levels, and also improve the satisfaction of diabetes treatment and reduce the frequency of hypoglycemia/hyperglycemia events in obese patients with type 2diabetic.

参考文献/References:

[1] Wang H, Lai Y. Urban- rural differences in diabetes in China [J]. JAMA,2017,317(16):1688-1689[2] Bommer C, Heesemann E, Sagalova V,et al. The global economic burden of diabetes in adults aged 20-79 years: a cost- of- illness study [J]. Lancet Diabetes Endocrinol, 2017,5(6):423-430. [3] Ibrahim M, Tuomilehto J, Aschner P, et al. Global status of diabetes prevention and prospects for action: a consen-sus statement [J]. Diabetes Metab Res Rev, 2018,34(6): e3021. [4] Dahlqvist S, Ahlen E, Filipsson K,etal. Variables associ-ated with HbA1c and weight reductions when adding Lira-glutide to multiple daily insulin injections in persons with type 2 diabetes [J]. BMJ Open Diabetes Res Care, 2018,6 (1):e000464. [5] Saisho Y. Use of diabetes treatment satisfaction question-naire in diabetes care: importance of patient-reported out-comes [J]. Int J Environ Res Public Health, 2018,15(5): E947. [6] Kalra S, Baruah MP, Sahay RK, et al. Glucagon- like peptide-1 receptor agonists in the treatment of type 2 dai-betes: past, present and future [J]. Indian J Endocrinol Metab,2016,20(2):254-267. [7] Davies M, Pratley R, Hammer M,et al. Liraglutide im-proves treatment satisfaction in people with type 2 diabetes compared with sitagliptin, each as an add on to metformin [J]. Diabet Med, 2011,28(3):333-337. [8] Rubing RR, Peyrot M. Health-related quality of life and treatment satisfaction in the Sensor- Augmented Pump Therapy for A1C reduction3 (STAR 3) trial [J]. Diabetes Technol Ther,2012,14(2):143-151. [9] W?gner AM, Miranda-Calderín G, Ugarte-Lopetegui MA. Effect of liraglutide on physical performance in type2 dia-betes: results of a randomized, double- blind, controlled trial (LIPER2) [J]. Diabetes Metab, 2019,45(3):268-275. [10] Andersen A, Christensen AS, Knop FK,et al. Glucagon-like peptide 1 receptor agonists for the treatment of type 2 diabetes [J]. Ugeskr Laeger,2019,181(12):10180725. [11] Ishii S, Nagai Y, Sada Y, et al. Liraglutide reduces vis-ceral and intrahepatic fat without significant loss of muscle mass in obese patients with type2 daibetes: a prospective case series [J]. J Clin Med Res, 2019,11(3):219-224. [12] Yamamoto S, Hayashi T, Ohara M,et al. Comparison of liraglutide plus basal insulin and basal-bolus insulin thera-py (BBIT) for glycemic control, body weight stability, and treatment satisfaction in patients treated using BBIT for type 2 diabetes without severe insulin deficiency: a random-ized prospective pilot study [J]. Diabetes Res Clin Pract, 2018,140:339-346. [13] Melzer- Cohen C, Chodick G, Husemoen LLN,et al. A retrospective database study of liraglutide persistence associ-ated with glycemic and body weight control in patients with type 2diabetes [J]. Diabetes Ther,2019,10(2):683-696. [14] Pokala N, Adams- Huet B, Li X, et al. The effect of baseline characteristics on clinical efficacy of liraglutide in patients treated with high-dose insulin [J]. Diabetes Obes Metab,2017,19(10):1454-1457.

备注/Memo

备注/Memo:

作者简介：顾晔，大学本科，主治医师，研究方向：内分泌 通信作者：顾晔，E-mail: ct6zz8@163.com

常用功能

更新日期/Last Update: 2020-02-28